Exegiline Pharma
Multifactorial Treatment of Alzheimer's Disease
Company Overview
Snapshot
Founded in December 2020 by Tal Youdim, Dr. Santiago Ini, Prof. Moussa Youdim, and Prof. Eli Heldman, Exegiline Pharma operates with 1–10 employees. The company has secured one funding round from one investor. In December 2020, Exegiline Pharma received seed funding from Youdim Pharmaceuticals.
Business overview
Exegiline Pharma is a Health Tech & Life Sciences company focused on developing novel oral drugs for the treatment of dementia and Alzheimer's disease. Its core product, MT-031, is a multifunctional drug designed to act as a dual acetylcholinesterase and butyrylcholinesterase inhibitor, with selective irreversible inhibition of MAO-A. MT-031 also exhibits anti-inflammatory, neuroprotective, and cognitive-enhancing properties, targeting the neurology and degenerative diseases market within the pharmaceutical sector.
Strategic signal
In April 2022, a news report highlighted a Parkinson's pioneer winning the Israel Prize, which is relevant to Exegiline Pharma's focus on neurological disorders and drug development. This recognition within the broader field of brain health research signals ongoing innovation and potential for advancements in related areas like Alzheimer's disease, aligning with Exegiline Pharma's mission to develop new treatments.
Company Intelligence Q&A
- What is Exegiline Pharma's primary focus?
- Exegiline Pharma is focused on the multifactorial treatment of Alzheimer's disease through the development of novel oral drugs.
- When was Exegiline Pharma founded?
- Exegiline Pharma was founded in December 2020.
- Who are the founders of Exegiline Pharma?
- The founders of Exegiline Pharma are Tal Youdim, Dr. Santiago Ini, Prof. Moussa Youdim, and Prof. Eli Heldman.
- What is MT-031?
- MT-031 is Exegiline Pharma's novel multifunctional oral drug candidate for the treatment of dementia and Alzheimer's disease, combining properties of rivastigmine and rasagiline.
- Has Exegiline Pharma secured any funding?
- In December 2020, Exegiline Pharma secured seed funding from Youdim Pharmaceuticals.